• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

    10/4/22 6:51:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email

    BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer.

    As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the Company's leadership positions and innovation through its plasma collection and donor management solutions, delivering on collectors' critical needs and supporting global demand for plasma-derived therapies. Additionally, Galvin will develop strategies to leverage Haemonetics' global footprint and blood component collection experience to expand in the non-commercial plasma market.

    Galvin joins Haemonetics after more than 25 years at Medtronic plc. His leadership roles within the company include Senior Vice President Commercial – US Cranial & Spinal Technologies; Senior Vice President Commercial Americas – Restorative Therapy Group; Vice President US Sales – Surgical Technologies; and Director of Global Marketing – Neurologic Technologies. Galvin's experience in global healthcare technology also includes positions at Xomed ENT prior to its acquisition by Medtronic, Corin Orthopedics, Biomet Corporation and Zimmer Orthopedic. He is a graduate of Portsmouth Polytechnic.

    "We are pleased to add Roy's vast experience at such an exciting time in our growth," said Simon. "As plasma volumes continue to recover and the industry strives to replenish supplies of life-saving medicines, Haemonetics is standing apart for providing the only fully-integrated solution addressing all of collectors' most pressing needs, improving productivity and throughput and lowering costs to collect. We also continue to help blood centers across the globe collect the blood components in the greatest demand, and attract and retain the right donors. We welcome Roy's leadership to help drive significant long-term results for our Plasma and Blood Center businesses."

    "Haemonetics has long been the established leader in the plasma and blood collection markets for solutions that make a meaningful difference for customers and the donors they serve. I look forward to helping the Company continue to distinguish itself for best-in-class products, a commitment to innovation and superior customer service and support," said Galvin.

    About Haemonetics

    Haemonetics (NYSE:HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

    Investor Contact:

    Media Contact:

    Olga Guyette, Sr. Director, Investor Relations & Treasury

    Josh Gitelson, Director, Global Communications

    (781) 356-9763   

    (781) 356-9776

    [email protected] 

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-appoints-roy-galvin-as-president-global-plasma-and-blood-center-301640053.html

    SOURCE Haemonetics Corporation

    Get the next $HAE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    8/8/2025$62.00Overweight → Neutral
    Analyst
    8/8/2025$95.00 → $86.00Outperform
    Barrington Research
    7/9/2025$90.00Neutral → Buy
    Citigroup
    6/26/2025$87.00Outperform
    Robert W. Baird
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $HAE
    SEC Filings

    View All

    SEC Form 10-Q filed by Haemonetics Corporation

    10-Q - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:08:06 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:04:03 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    7/25/25 4:16:54 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

    Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures. The submission builds upon the successful results of the PATCH study as well as positive clinical use in Europe, reinforcing the system's potential safety and performance profile. In addition, the company received European CE mark approval for an expanded indication for PerQseal Elite

    6/24/25 8:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zane Ellen M was granted 2,693 shares, increasing direct ownership by 16% to 19,373 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:36:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Pomeroy Claire was granted 2,693 shares, increasing direct ownership by 19% to 16,872 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:33:39 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Kroll Mark W was granted 2,693 shares, increasing direct ownership by 13% to 23,357 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:30:46 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics downgraded by Raymond James with a new price target

    Raymond James downgraded Haemonetics from Strong Buy to Outperform and set a new price target of $78.00

    8/11/25 9:46:26 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics downgraded by Analyst with a new price target

    Analyst downgraded Haemonetics from Overweight to Neutral and set a new price target of $62.00

    8/8/25 8:19:52 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $86.00 from $95.00 previously

    8/8/25 7:34:13 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Financials

    Live finance-specific insights

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

    5/8/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

    BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

    10/4/22 6:51:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/12/24 12:54:20 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/8/24 10:41:07 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care